Literature DB >> 3278234

Prophylaxis of gonococcal and chlamydial ophthalmia neonatorum. A comparison of silver nitrate and tetracycline.

M Laga1, F A Plummer, P Piot, P Datta, W Namaara, J O Ndinya-Achola, H Nzanze, G Maitha, A R Ronald, H O Pamba.   

Abstract

We evaluated the use of silver nitrate drops and tetracycline ointment for the prophylaxis of ophthalmia neonatorum in a controlled trial involving 2732 newborns in Nairobi, Kenya. The overall rates of prevalence of intrapartum maternal gonococcal and chlamydial infection were 6.4 and 8.9 percent, respectively. After prophylaxis with silver nitrate, the incidence rates of gonococcal, chlamydial, and nongonococcal, nonchlamydial ophthalmia neonatorum were 0.4, 0.7, and 6.2 percent, respectively, whereas after prophylaxis with tetracycline, the rates were 0.1, 0.5, and 4.5 percent. The attack rates of gonococcal ophthalmia neonatorum in newborns exposed to Neisseria gonorrhoeae at birth were 7.0 percent in those receiving silver nitrate and 3.0 percent in those receiving tetracycline (95 percent confidence interval for the difference in rates, -3.4 to 11.4 percent). As compared with historical controls, the incidence of gonococcal ophthalmia neonatorum decreased 83 percent among infants treated with silver nitrate and 93 percent among those treated with tetracycline. Failure of prophylaxis was associated with postpartum maternal endometritis (P = 0.05). Among newborns exposed to maternal infection with Chlamydia trachomatis, chlamydial conjunctivitis developed in 10.1 percent given silver nitrate and in 7.2 percent given tetracycline (95 percent confidence interval for the difference in rates, -4.7 to 10.5 percent), yielding reductions in the incidence of chlamydial ophthalmia of 68 and 77 percent, respectively, as compared with the historical controls. We conclude that tetracycline is as effective as silver nitrate in preventing gonococcal ophthalmia neonatorum.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278234     DOI: 10.1056/NEJM198803173181101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

Review 1.  Periodic health examination, 1992 update: 4. Prophylaxis for gonococcal and chlamydial ophthalmia neonatorum. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

2.  The dilemma of neonatal ophthalmic prophylaxis.

Authors:  S J Isenberg
Journal:  West J Med       Date:  1990-08

3.  Eminent venereologists 5: Carl Credé.

Authors:  J D Oriel
Journal:  Genitourin Med       Date:  1991-02

Review 4.  Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries.

Authors:  S Mullick; D Watson-Jones; M Beksinska; D Mabey
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 5.  The role of epidemiology and surveillance systems in the control of sexually transmitted diseases.

Authors:  M A Catchpole
Journal:  Genitourin Med       Date:  1996-10

Review 6.  A review of HIV-1 in Africa.

Authors:  A R Ronald; J O Ndinya-Achola; F A Plummer; J N Simonsen; D W Cameron; E N Ngugi; H Pamba
Journal:  Bull N Y Acad Med       Date:  1988 Jul-Aug

7.  Antimicrobial susceptibility of Neisseria gonorrhoeae in Zaire: high level plasmid-mediated tetracycline resistance in central Africa.

Authors:  E Van Dyck; R Rossau; M Duhamel; F Behets; M Laga; M Nzila; S Bygdeman; H Van Heuverswijn; P Piot
Journal:  Genitourin Med       Date:  1992-04

Review 8.  STD in children: syphilis and gonorrhoea.

Authors:  S A Rawstron; K Bromberg; M R Hammerschlag
Journal:  Genitourin Med       Date:  1993-02

Review 9.  Sexually transmitted diseases in children: chlamydial oculo-genital infection.

Authors:  B T Goh; G E Forster
Journal:  Genitourin Med       Date:  1993-06

Review 10.  Epidemiology of sexually transmitted diseases: the global picture.

Authors:  A De Schryver; A Meheus
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.